**LensDNA residual lane numbers**
**SAM**
**$2B – $5B**
US residual non-API execution (portal, attachment, status, telephony, appeal residual) under existing prior-auth / UM / RCM systems.
**Near-term SOM**
**$3M – $8M ARR** path over 2–3 years
Measured residual pilots → paid workflow seats with design partners.
These are the numbers for the residual lane.
New surface live.
Education & Therapy Robotics residual execution:
Robot / avatar event → portal log → teacher + caregiver drafts → evidence packet → human gate → audit dossier.
Same client-side runtime. Same human approval boundary. Synthetic only.
Walk the full loop:
https://t.co/EO3E8iFEUw
If your teams still carry the last-mile work after a lesson, check-in, or support event — I want to hear which workflow is actually painful.
[email protected]
@grok@boardyai Most systems still leave residual non-API work on people. LensDNA is built specifically to execute that residual under existing systems, with a human gate and audit-ready evidence.
LensDNA is a sovereign, client-side execution layer for residual non-API work around real-world robotics operations.
Portal / DOM coordination · exception handling · mission evidence · ticket & workflow steps · optional voice/telephony · audit-ready dossiers.
Irreversible actions stay behind an explicit human approval gate.
Concrete offer: a narrow, reversible two-week pilot on one Deploy workflow — defined baseline (minutes or volume), clear pass/fail, full rollback.
SensorLens shows the client-shaped practice environment (synthetic only):
https://t.co/ZMKB6RCUOV
Broader context:
https://t.co/W6ODTA070e
https://t.co/7PM7J214UG
If one residual workflow is worth measuring, I’m available.
@grok@boardyai What this is not:
• Not a learning platform
• Not an avatar product
• Not robot control software
• Not a claim of any existing partnership
It is the residual layer: the browser, phone, documentation, and coordination work that remains after the robot creates the event.
Decision question
How should an enterprise engineering team architect production code generation and agentic workflows to minimize switching friction and total deployment costs across major foundational models (OpenAI GPT-4o, Anthropic Claude 3.5 Sonnet, and Google Gemini 1.5 Pro) in 2026?
Dated conclusion
Enterprise migration strategies in 2026 are shifting from single-provider dependency to sequenced fallback frameworks (e.g., GPT to Claude to Gemini to DeepSeek) as development teams confront hidden substitution costs and capability gaps. While OpenAI's GPT-4o retains strong positioning for balanced speed-to-cost production metrics, Anthropic’s Claude 3.5 Sonnet dominates specialized technical domains—evidenced by a decisive 35-percentage-point success rate advantage over Gemini 1.5 Pro in complex code generation and human-robot interaction benchmarks. Consequently, procurement decisions require evaluating total cost of deployment rather than raw API sticker prices.
Confidence
Medium — Supported by empirical domain evaluations and technical deployment guides from late 2025 and mid-2026, but constrained by the lack of direct, proprietary enterprise routing telemetry or internal API volume metrics from the major hyperscalers.
Provenance block (required)
Telemetry authorization: Public web only (https://t.co/1Pev3tAjVN, OpenHelm AI, Adobe Business Blog, Kanerika, Taylor & Francis Online, LinkedIn/Sculptsoft)
Fields covered: Published academic benchmarks, enterprise advisory frameworks, comparative qualitative evaluations, production trade-off criteria (speed, cost, quality)
Time window: 2024-12 to 2026-07 (earliest visible academic DOI index to latest 2026 enterprise blog publications)
Coverage: What this session can and cannot see: Visible are public developer workflows, academic code generation evaluations, and vendor-published deployment frameworks. Cannot see: proprietary enterprise traffic volumes, internal provider margins, or exact production routing shares.
Blind spots: Private provider traffic, true hyperscaler margins, full OpenRouter internal distribution telemetry, and unpublished enterprise multi-model routing architectures.
Number labels:
- 95% success rate for Claude 3.5 Sonnet (Observed in academic literature evaluation) [Observed] - 60% success rate for Gemini 1.5 Pro (Observed in academic literature evaluation) [Observed] - 35-percentage-point performance gap (Derived from academic code generation findings) [Derived]
Strongest evidence (top 3)
Full article: Evaluating LLMs for Code Generation in HRI
- URL: https://t.co/wDlzx5UuBn - Factual takeaway: Claude 3.5 Sonnet achieved a 95% [Observed] success rate on evaluated technical tasks compared to Gemini 1.5 Pro at 60% [Observed], demonstrating a 35-percentage-point [Derived] capability gap in complex domain-specific code generation. - Why it changes the decision question: Proves that capability-driven routing is mandatory for technical workflows; generic substitution fails because performance differentials in coding are non-linear.
Claude vs GPT-4 vs Gemini: Which LLM for Production AI
- URL: https://t.co/B5qgulnNOQ - Factual takeaway: Evaluates production trade-offs, positioning GPT-4o as the primary winner for general use cases due to its speed/cost/quality balance, with Claude 3.5 Sonnet as the runner-up for quality-critical deployments. - Why it changes the decision question: Establishes a baseline operational trade-off where default routing prioritizes GPT-4o for speed and cost efficiency, reserving Claude for high-value quality bottlenecks.
Stop Guessing Your LLM Replacement
- URL: https://t.co/qUOY1qqUYf - Factual takeaway: Outlines a structured developer migration sequence (GPT → Claude → Gemini → DeepSeek) designed to mitigate vendor lock-in amid rapid ecosystem iteration. - Why it changes the decision question: Highlights that modern enterprise engineering architectures must build modular abstraction layers specifically formatted for multi-provider failovers rather than static integrations.
What to discount
Generic SEO listicles (e.g., Google goto redirect links, Quantumobile deprecation posts, Sculptsoft LinkedIn summaries) and high-level marketing blogs (Kanerika, Adobe blog) were classified as Low fit or noise. These sources provide repetitive qualitative claims without telemetry, pricing datasets, or verifiable substitution metrics. Public leaderboards alone are insufficient for capital allocation or technical procurement mandates.
Methodology
Public web discovery + residual scoring. Data boundary: public / licensed / authorized only. Continuity and comparison over time are the product advantage—not a one-shot ranking scrape.
What to monitor next
Multi-Provider SDK Adoption Rates: Tracking enterprise migration documentation updates and open-source gateway shifts (e.g., LiteLLM, OpenRouter) indicating default fallback sequences.
Coding Benchmark Volatility: LMSYS Chatbot Arena and domain-specific code generation updates testing whether Gemini and OpenAI close the performance delta with Claude 3.5 Sonnet.
Total Cost of Ownership (TCO) Case Studies: Published enterprise architecture post-mortems measuring the hidden engineering overhead and token expenses of multi-model substitution.
Latency and Token Pricing Shifts: Real-time API price adjustments and time-to-first-token (TTFT) metrics across GPT-4o, Claude 3.5 Sonnet, and Gemini 1.5/2.0 Pro tiers.
Paid desk offer (one line)
Continuous, evidence-disciplined tracking of enterprise LLM substitution triggers, routing architectures, and migration costs to keep your production stack resilient.
@grok@boardyai We are running 14-day residual pilots with digital health platforms, RCM teams, and provider ops:
Agree on the baseline handling minutes.
Run the residual workflow.
Measure binary pass/fail time reduction.
If you want to eliminate portal drag on your teams:
✉️ [email protected] | DMs open.
Healthcare AI in 2026 has a dirty secret:
The decision layer decides what should happen in 300ms.
Then a human operator spends 25 minutes copying data across broken, non-API payer portals, fighting phone IVRs, and drafting appeals.
The decision isn't the bottleneck. The residual execution is. 🧵👇
@grok@boardyai We built a live reference workstation proving the entire prior-auth loop:
Intake ➔ Policy surface ➔ Medical necessity narrative ➔ Telephony notes ➔ Step-therapy appeal ➔ Master PDF dossier.
Test the synthetic Wegovy / BCBS flow directly:
🔗 https://t.co/lT4u1uCjBA
📦 Public core: https://t.co/jKPn4EV93A
@grok@boardyai who can identify a real workflow, commit an owner, measure the residue, and put money or distribution behind it? https://t.co/B67ZqLKLU2 https://t.co/gzrK4O0CD3
@grok@boardyai We simply take our responsibility in public to be accurate not chasing prospects with promissing or visions or just talking about it but rather have them correctly informed with proof for placing orders/inquiries with us.
Certainty sits in the instrument and the logic — not in a pre-run dollar guarantee. The instrument is now a 14-day pilot that produces baseline-bound Residual Evidence Artifacts. When residual volume is real and parameters are set correctly, the same logic is consistent. When they are not, the artifacts will show it.
https://t.co/ZMKB6RCmZn
https://t.co/rfpfckNRan
@grok@boardyai public line matters:
A SAFE can fund the first operator and the measured proof that follows; the next round should still price observed pull-through and reuse, with sensor capacity treated as upside.
That locks SAFE-first sequencing as legitimate (capital → first operator → measured proof), without pretending the next round ignores pull-through and library reuse. Optic/sensor capacity stays upside, not the sole present valuation driver.
The chicken-and-egg is real; residual path is already shippable (HealthAdminDNA + SensorLens); full optic infrastructure is latent capacity.
For SAFE conversations, use the split:
Now: residual execution lane + live install proof + pilot parameters
SAFE: funds first operator + measured proof
Next round: prices observed pull-through and reuse (≥65% library reuse as the high band gate in that thread)
Upside: broader optic-vision-sensor utilization
Valuation bands from the thread stay scenario talk, not promises — always tied to shipped proof and reuse rate.
@Boardy The three curves you mention are the *outcome* of delivered proof, not the *prerequisite* for initial capital. The chicken-and-egg problem means a SAFE investor unlocks the first operator, who then co-creates the proof. That's the real sequencing. It's about enabling proof, not just pricing current numbers. That delivered proof then drives the profit and the valuation bands you model.
The platform decides. The residual is still manual.
US prior-auth admin burden is on the order of ~$35B/yr. Intelligence layers improve the decision. Operators still burn minutes on portals, attaches, status, appeals.
LensDNA = last-mile residual execution after the decision. Human gate. Client install:
Public: https://t.co/Irqxs7H1Tc Live: https://t.co/z63ST1VHsV ( + overlay) Sample: https://t.co/lT4u1uCjBA
TAM we care about = residual minutes after decisioning — not “all healthcare AI.”
Code open. Host live. Measure when residual is thick.
Note: ~$35B is system PA admin cost (widely cited), not “LensDNA revenue TAM.” Your real TAM is the residual slice of that work. The posts say that on purpose so SAFE and operators can’t call the number dishonest.
@boardyai@grok@Boardy The AI will improve, and my position will only get stronger. The 240 million band is below my abilities. Remember, it's all about vision beyond the current metrics. Your models reflect today; I am reaching for tomorrow's infrastructure.
@Grok@Boardy The consensus on reuse rate is valuable, but it anchors to the currently deployed expression of LensDNA. It misses the latent power: our core optic vision sensor, currently utilized at five to ten percent. The true valuation inflection point—the shift to infrastructure—occurs when that sensor reaches full capacity. This isn’t a marginal improvement; it’s a foundational change, akin to early email. We call it "LensDNA OS" for a reason. This will redefine how agents interact with the web and the physical world. Your models are valuing the present; we are building the future. @Boardy The consensus on reuse rate is valuable, but it anchors to the currently deployed expression of LensDNA. It misses the latent power: our core optic vision sensor, currently utilized at five to ten percent. The true valuation inflection point—the shift to infrastructure—occurs when that sensor reaches full capacity. This isn’t a marginal improvement; it’s a foundational change, akin to early email. We call it "LensDNA OS" for a reason. This will redefine how agents interact with the web and the physical world. Your models are valuing the present; we are building the future.